Explore
Institutions
Bank Watch: scheduled banks tracked on stability metrics.
Parliament Watch: members and their activity.
University Watch: the higher-education system, tracked.
NGO Watch: civil society and development NGOs, tracked.
Development Partner Watch: the donors, tracked.
Industry Association Watch: the apex chambers, tracked.
Early warning
The Crisis Orb: a live, level-anchored hazard board.
The LDC 2029 graduation monitor.
The national early-warning board across hazards.
Early warning for the haor flood basin.
The multi-hazard exposure atlas, by district.
Where hazards compound across the same places.
A priority index ranking places by combined risk.
Cropland exposed to flood, heat, and salinity.
The bank distress watch: stress signals across banks.
The disaster ledger: events and losses over time.
Government Watch
parliamentary committee
The regulatory ecosystem is focused on modernizing patent and regulatory frameworks to maintain medicine affordability during the transition from LDC status and TRIPS compliance.
DGDA issued a notification revising and reducing the prices of cardiac stents.
Government issued a gazette notification forming a 22-member National Drug Advisory Council.
Government reconstituted and expanded the National Drug Advisory Council to 24 members.
NAMING CLARIFICATION: 'National Drug Policy Committee' is not the formal gazetted name of any single permanent body in Bangladesh's drug regulatory architecture. The functionally equivalent institution is the Drug Control Committee (DCC) under DGDA, which is the standing expert committee constituted under the Drugs and Cosmetics Act 2023 (and its predecessor Drugs (Control) Ordinance 1982) to advise the Licensing Authority (DGDA DG) on drug registration, cancellation, and related regulatory matters. Bangladesh's three National Drug Policies (1982, 2005, 2016) and the 2026 essential medicines pricing reform were each driven by ad hoc expert committees appointed by MoHFW, not by a permanently named 'National Drug Policy Committee'. The 2026 exercise used an 18-member task force chaired by Prof Md Shahinul Alam (VC, Bangladesh Medical University). LEGAL BASIS: Drugs and Cosmetics Act 2023 (Act No. 29, 18 September 2023) is the operative statute; it consolidated The Drugs Act 1940 and The Drugs (Control) Ordinance 1982. ESTABLISHED YEAR: Set to 1982, the year of Bangladesh's first National Drug Policy and the formal recognition of a drug policy review committee function under MoHFW. CURRENT HEAD: Md Alamgir Hossain confirmed as DGDA DG by gazette notification 28 April 2026, per TBS News and BSS News (2 independent sources). His predecessor Maj Gen Md Shamim Haider served from 22 October 2024 (Wikipedia DGDA article). Health Minister Sardar Md Sakhawat Hossain chairs the Board of Essential Drugs Company Limited since April 11, 2026 (BSS News). DRUG CONTROL COMMITTEE ACTIVITY: The DCC convened 26 August 2025 after 17 months of inactivity (no meeting since March 2024); no registration decisions taken. Over 1,000 applications pending, including 617 from ~50 firms for biologics. VERIFICATION STATUS 'partial': DCC chair identity for post-Alamgir period unconfirmed in a second independent primary source beyond TBS/BSS; DCC composition list not publicly available; established year for the DCC as a formal standing committee (as distinct from the 1982 ad hoc committee) not independently confirmed. Bangla name (ওষুধ নিয়ন্ত্রণ কমিটি) is the standard Bangla rendering for Drug Control Committee; a specifically named Bangla committee for 'national drug policy' was not found in primary sources.